找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy; Vassil St.Georgiev,Gail Skowron (Chief),Joep M. A. Book 2006 Humana Press 2006 AIDS.

[復(fù)制鏈接]
查看: 6757|回復(fù): 59
樓主
發(fā)表于 2025-3-21 16:06:25 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy
編輯Vassil St.Georgiev,Gail Skowron (Chief),Joep M. A.
視頻videohttp://file.papertrans.cn/830/829407/829407.mp4
概述Includes supplementary material:
叢書(shū)名稱(chēng)Infectious Disease
圖書(shū)封面Titlebook: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy;  Vassil St.Georgiev,Gail Skowron (Chief),Joep M. A. Book 2006 Humana Press 2006 AIDS.
描述A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.
出版日期Book 2006
關(guān)鍵詞AIDS; HIV; HIV/AIDS; drug; drug discovery; drug resistance; kinetics; pharmacokinetics; pharmacology; prevent
版次1
doihttps://doi.org/10.1007/978-1-59745-085-0
isbn_softcover978-1-61737-695-5
isbn_ebook978-1-59745-085-0
copyrightHumana Press 2006
The information of publication is updating

書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy影響因子(影響力)




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy被引頻次




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy被引頻次學(xué)科排名




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy年度引用




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy年度引用學(xué)科排名




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy讀者反饋




書(shū)目名稱(chēng)Reverse Transcriptase Inhibitors in HIV/AIDS Therapy讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶(hù)組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:40:35 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:47:10 | 只看該作者
Zidovudine, Lamivudine, and Abacavir,ot only because it was the first Food and Drug Administration (FDA)-approved agent for the treatment of HIV, but for the unprecedented speed with which this drug moved through the new-drug approval process (Table 1). In March 1987, ZDV was approved by the FDA for use in HIV-infected individuals with
地板
發(fā)表于 2025-3-22 05:36:09 | 只看該作者
Stavudine, Didanosine, and Zalcitabine,nd in 1987, researchers logically turned to other nucleoside analogs in an attempt to expand the armamentarium against the disease. The next three compounds in this class to become commercially available were didanosine (as Videx?, Bristol Myers Squibb) in 1991, zalcitabine (as Hivid?, F. Hoffmann-L
5#
發(fā)表于 2025-3-22 12:46:08 | 只看該作者
Emtricitabine,ering only in having a fluoride at the 5-position of the cytosine ring. Emtricitabine is the (& minus) enantiomer, which is more active than the (+) enantiomer. Emtricitabine has a long plasma half-life (10 h), and even longer intracellular half-life of the active triphosphate (39 h), supporting onc
6#
發(fā)表于 2025-3-22 16:16:06 | 只看該作者
7#
發(fā)表于 2025-3-22 17:05:03 | 只看該作者
8#
發(fā)表于 2025-3-23 00:41:07 | 只看該作者
9#
發(fā)表于 2025-3-23 03:33:11 | 只看該作者
10#
發(fā)表于 2025-3-23 06:56:41 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 12:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
蒙阴县| 锡林浩特市| 商都县| 龙陵县| 忻州市| 乾安县| 冷水江市| 贡觉县| 高要市| 太仓市| 瑞金市| 新竹县| 论坛| 常州市| 康平县| 紫阳县| 利津县| 安泽县| 富锦市| 中宁县| 张家港市| 黎城县| 临沂市| 泸定县| 清河县| 九江县| 边坝县| 西安市| 绥德县| 鄂尔多斯市| 伊吾县| 高台县| 古交市| 巴彦县| 高唐县| 荔浦县| 定边县| 南宁市| 略阳县| 来宾市| 龙南县|